Comprehensive Stock Analysis Of Opko Health, Inc. (OPK)

Perhaps, that suggests something about why 6.84% of the outstanding share supply is held by institutional investors. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Guggenheim started coverage on shares of Opko Health in a research report on Tuesday, March 14th. The shares were acquired at an average price of $7.85 per share, for a total transaction of $45,530.00. Outperform is an analyst recommendation meaning a stock is expected to do slightly better than the market return.

Moving toward the volatility measures, the price volatility of stock was 1.31% for a week and 1.13% for a month as well as price volatility's Average True Range for 14 days was 0.55.

Opko Health Inc (NYSE:OPK) reported having received $-0.0455 for each of its share from its parent company in the annual period ended 2016-12-31. The stock has been recently recorded -35.31% off of the 52-week high of 12.15 and +10.24% away from the 52-week low of 7.13. (NASDAQ:OPK) observed rebound of 12.2% since bottoming out at $7.13 on March 02, 2017. The company had a trading volume of 1,198,538 shares. The stock is now moving above its 20-Day Simple Moving Average of -6.73% with the 50-Day Simple Moving Average of -6.73 percent. Now trading with a market value of 4.39B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. While the actual EPS the company reported in the same quarter previous year was -0.02/share. Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%.

Opko Health, Inc. (NASDAQ:OPK) yearly performance is -29.88% and net profit margin is -2.10%. The Average Volume of the company is 4.87 Million and P/E (price to earnings) ratio is 0, while Forward P/E ratio is 145.

Analysts estimated $-0.04/share for the previous Quarter, where Opko Health, Inc. The research firm Initiated the stock to Buy. (NASDAQ:CLDX) need to consider for profitability analysis, in latest session share price swings at $3.17 with percentage change of -5.93%. In a report issued on March 14, Guggenheim analyst Louise Chen initiated coverage with a Buy rating on OPK and a price target of $25, which represents a potential upside of 218% from where the stock is now trading. Zacks Investment Research downgraded shares of Opko Health from a "hold" rating to a "sell" rating in a research note on Wednesday, January 18th. Separately, on March 3, Standpoint Research's Ronnie Moas reiterated a Buy rating on the stock and has a price target of $14. Finally, TheStreet downgraded shares of Opko Health from a "c-" rating to a "d+" rating in a research note on Wednesday, February 1st. The stock went down -32.99% at some stage in past quarter.

Opko Health, Inc. (OPK) topped its 52-week high price target of 12.15 on Dec 15, 2016.

The stock was able to keep return on assets at 0.85% in the trailing twelve month while Reuters data showed that industry's average stands at 2.30% and sector's optimum level is 2.41%. AQR Capital Management LLC purchased a new stake in shares of Opko Health during the fourth quarter worth about $105,000. Envestnet Asset Management Inc. now owns 15,355 shares of the company's stock worth $142,000 after buying an additional 2,927 shares during the last quarter. The stock is showing its Operating Margin of -6 percent.

In the last Quarter, Opko Health, Inc. The short ratio in the company's stock is documented at 15.29 and the short float is around of 22.09%. It operates in two segments: pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The Diagnostics segment is primarily comprised of the clinical and laboratory operations tit acquired through the acquisition of Bio-Reference and OPKO Lab and its point-of-care operations.



Other news